A missed endpoint, a safety signal, a Complete Response Letter – each one triggers two crises at the same time: investors who need to know what it means for the stock and the raise, and patients, caregivers, and HCPs who need to know what it means for their treatment. Most biotech companies have an IR firm on retainer for the first audience and nobody assigned to the second. Winston Francois builds and runs the patient and HCP-facing response before the disclosure goes out, not after the story starts writing itself.
The Problem
Your IR Firm Doesn't Talk to Patients
IR firms are built for one audience – analysts and shareholders – and they write in that register. When a trial misses its primary endpoint, the 8-K goes out on schedule, but the patients on that drug, their caregivers, and the physicians prescribing it get nothing built for them. They find out from a headline, a patient forum, or a nurse who read the same news they did. That gap turns a clinical setback into a trust problem you didn't need to have.
The Clock Starts Before Legal Signs Off
Material disclosure rules force the investor-facing statement out fast, usually within four business days of a triggering event. Patient and HCP communication has no equivalent deadline, so it gets deprioritized until legal and IR finish their draft – meaning the people most directly affected by a hold or a safety signal wait the longest for a straight answer. By the time the company reaches them, someone else has already told the story.
One Message Doesn't Work for Both Rooms
A board and analysts want risk quantified: what changes for the pipeline, the cash runway, the next catalyst. A patient on the drug wants a different question answered: is my treatment safe, does this change my next dose, who do I call. Send the investor version to a caregiver and you sound clinical and cold. Send the patient version to a fund and you sound like you're hiding the financial exposure. Companies without a dual-track plan default to one voice and lose the other audience.
Nobody Owns This Until It's Already a Crisis
Ask most biotech leadership teams who's responsible for patient and HCP communication during a clinical setback and you get a pause, then "medical affairs, probably" or "whoever's around." That's not a plan, it's an assumption that gets tested for the first time during the worst week of the company's life. Without a named owner, a pre-approved decision tree, and drafted templates sitting ready, the first 24 hours after disclosure get spent arguing about who should be talking, not talking.
How We Help
We start by mapping every disclosure trigger your company could face in the next 18 months against who actually needs to hear about it and how fast: missed primary or secondary endpoints, unexpected adverse events, a partial or full clinical hold, a Complete Response Letter, a safety signal from a post-marketing study.
Then we build the message architecture – not a single crisis statement, but parallel tracks written for investors, for patients currently on the drug or in the trial, for prescribing physicians, and for caregivers, each answering the specific question that audience actually has. The investor track stays with your IR team and outside counsel; we don't touch securities disclosure.
We draft holding statements, FAQ documents, physician talking points, and patient support-line scripts in advance, before any trigger event happens, so the moment something breaks you're editing pre-approved language for specifics instead of writing from scratch under pressure.
We build a decision tree that names who activates each track, who approves language for each audience, and what channel each message goes out on – patient portal, HCP email, advocacy group liaison, press. This removes the argument about ownership that otherwise burns your first six hours.
Before we call the engagement done, we run at least one live tabletop exercise with your leadership team and medical affairs, simulating a real trigger – a safety signal or a missed endpoint – and timing how fast the patient and HCP tracks actually go out. We adjust the plan based on where it breaks in practice, not in theory.
Once the framework is live, we track two things going forward: response time from trigger to first patient or HCP communication, and the volume and tone of inbound questions to your patient support line and medical information team in the 72 hours after a disclosure. Both tell you whether the plan is absorbing the shock or just sitting in a drawer.
What we deliver
- Disclosure Trigger Map – every clinical and regulatory event that could force a dual-audience response, mapped to the specific patient, HCP, and caregiver groups affected.
- Pre-Approved Message Library – holding statements, FAQs, physician talking points, and patient support scripts cleared by medical, legal, and regulatory before any event occurs.
- Activation Decision Tree – a single document naming who triggers each communication track, who approves language, and which channel carries it, so the first hour isn't spent arguing about ownership.
- Tabletop Drill and After-Action Report – a live simulation of a real trigger event with your leadership team, timed and scored, with specific fixes to the plan based on where it broke.
Your IR firm has four business days to file the 8-K. The patient on your drug wants an answer in four hours – and right now, nobody's assigned to give it to them.
Our Methodology
We run this as a 90-day build, not an open-ended retainer dressed up as strategy. The first 30 days are trigger mapping and audience assessment – we're not writing anything yet, we're figuring out exactly what could happen and who it hits. Days 30 to 60 are message architecture and drafting: the templates, the FAQs, the scripts, run through your review chain in parallel instead of in sequence, which is where most companies lose weeks.
Days 60 to 90 are activation infrastructure and the live drill – the decision tree, the channel mapping, and a real tabletop exercise with your team that either proves the plan works or shows us exactly where to fix it before a real event does. Nobody signs off on a crisis plan they haven't stress-tested.
After 90 days, most clients keep us on a lighter monitoring retainer – we update the trigger map as your pipeline changes, refresh templates against new data readouts, and rerun the drill roughly twice a year. The heavy lift is front-loaded on purpose, because the point is to have this ready before you need it, not while you need it.
How We Work
You'll work directly with a senior crisis communications lead who has run this exact playbook before, not an account team that hands your file to a junior after the pitch. That person sits in on your key medical affairs and IR calls during the build so the patient and HCP track stays consistent with what your investor-facing team is saying, without either team having to translate for the other.
In the first 30 days, expect two to three working sessions with medical affairs, regulatory, and whoever currently fields patient calls, plus a review of every disclosure event your program has faced or could face given where the pipeline sits. By day 30 you have the trigger map and a prioritized list of what to build first.
Days 30 to 60 are heads-down drafting with weekly check-ins, not daily status updates – we're not going to manufacture busywork to justify a fee. Your legal and regulatory reviewers see drafts in batches so their time isn't fragmented across a dozen small asks.
The final 30 days is where you'll feel the difference: a live drill with your leadership team, a scored after-action report, and a plan that's actually been through a dry run instead of just looking good in a slide deck. After that, cadence drops to quarterly check-ins unless your pipeline hits a new milestone that changes the trigger map.
- Faster time from disclosure to first patient/HCP communication, measured against your own prior baseline.
- A named, rehearsed chain of ownership so the first hours after a trigger event are spent executing, not debating who's in charge.
- Consistent messaging across investor and patient-facing channels, reducing the risk that mismatched statements become their own story.
If your biotech & pharma company needs crisis communications leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does this cost?
Most crisis communications engagements for biotech and pharma companies run $15,000 to $35,000 per month during the 90-day build, depending on how many trigger scenarios and audience segments your pipeline requires. A company with a single late-stage asset needs less scenario planning than one running multiple trials across different indications.
How long until we have a working crisis plan?
The full build is 90 days, but you're not exposed for all of it. Draft holding statements and an interim decision tree are usually ready by day 45, well before the full message library and tabletop drill are complete.
How does this work with our existing IR and legal teams?
We don't replace your IR firm or outside counsel, and we don't touch securities disclosure – that stays exactly where it is. Our work is the patient, HCP, and caregiver track that currently has no owner.
How is this different from hiring a standard crisis PR agency?
Most crisis PR agencies are built for reputation management after something goes wrong in the press – they know how to handle a hostile reporter, not how to write a dosing continuity FAQ for a patient on an investigational drug. We build specifically for the clinical and regulatory triggers biotech and pharma companies actually face, with medical affairs and regulatory review built into the process from day one, not added after a first draft gets rejected by legal.
How do you measure whether this is working?
We track response time from trigger event to first patient and HCP communication, compared to your prior baseline, and we track the volume and content of inbound calls to your patient support line and medical information team in the days after a disclosure. A working plan shows faster response times and fewer confused or angry inbound calls asking questions your materials should have already answered.
What kind of company is this built for?
This is built for Series A through growth-stage biotech and pharma companies with an asset in the clinic or on the market – meaning there's an actual trial population or patient base that a disclosure event would affect. If you're pre-clinical with no patients or prescribers yet, you don't need this yet.
